News
Valneva Announces The Initiation Of Phase 1 Trial Of Second-Generation Zika Vaccine Candidate
26 Mar 24
News
What Analysts Are Saying About Valneva Stock
22 Mar 24
Analyst Ratings
Guggenheim Maintains Buy on Valneva, Lowers Price Target to $17
22 Mar 24
News, Price Target, Analyst Ratings
Valneva Raised 2024 Product Sales Guidance To €160M-€180M (Prior €150M-€180M); Sees Total Revenues Of €170M-€190M
20 Mar 24
Earnings, News, Guidance
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
19 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Valneva Extends Interest-Only Payment Term For Its Loan Facility With Deerfield and OrbiMed
18 Mar 24
News
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
8 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $26 Price Target
29 Feb 24
News, Price Target, Reiteration, Analyst Ratings
U.S. Centers For Disease Control And Prevention's Advisory Committee Recommends Use Of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ®
29 Feb 24
News
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $26 Price Target
15 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Valneva's 2024 Guidance: Expects Product Sales Of €150M-€180M, Reflecting Continued Revenue Growth For Proprietary Products And IXCHIQ®'S Launch-Year Sales
15 Feb 24
Earnings, News, Guidance
Valneva's 2023 Revenues €153.7M, Down From €361.3M YoY; Product Sales Grew 26% YoY To €144.6M
15 Feb 24
Earnings, News, New ETFs, ETFs
Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline
5 Feb 24
Biotech, News, Health Care, Financing, FDA, General
McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday
5 Feb 24
Earnings, News, Small Cap, Pre-Market Outlook, Markets, Trading Ideas
Valneva Sells Priority Review Voucher From The U.S. Food And Drug Administration For $103M
5 Feb 24
News
Press releases
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
26 Mar 24
Press Releases, General
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
25 Mar 24
Press Releases
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
21 Mar 24
Press Releases, General
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
20 Mar 24
Earnings, Press Releases
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
18 Mar 24
News, Press Releases
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
4 Mar 24
News, Press Releases
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ®
29 Feb 24
Press Releases, General
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
15 Feb 24
Earnings, Press Releases
Valneva Announces Sale of Priority Review Voucher for $103 Million
5 Feb 24
Press Releases